Shares of GlaxoSmithKline Pharmaceuticals declined 2.15%, trading at Rs 2,748.00 in Tuesday's session. The stock is among the top losers on the Nifty Midcap 150 index.
GlaxoSmithKline Pharmaceuticals, as per Moneycontrol analysis on August 28, 2025, showed very bearish sentiment.
GlaxoSmithKline Pharmaceuticals Financials
Here is a look at the consolidated quarterly financials of GlaxoSmithKline Pharmaceuticals:
| Heading | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|
| Revenue | Rs 814.65 Crore | Rs 1,010.77 Crore | Rs 949.42 Crore | Rs 974.37 Crore | Rs 805.17 Crore |
| Net Profit | Rs 182.33 Crore | Rs 252.50 Crore | Rs 229.88 Crore | Rs 262.87 Crore | Rs 205.01 Crore |
| EPS | 10.76 | 14.91 | 13.57 | 15.52 | 12.10 |
The revenue for the quarter ending June 2025 stood at Rs 805.17 Crore, while in the previous quarter ending March 2025, revenue was at Rs 974.37 Crore. The net profit for the June 2025 quarter was Rs 205.01 Crore, compared to Rs 262.87 Crore in the March 2025 quarter. Earnings per share (EPS) for June 2025 stood at 12.10, down from 15.52 in March 2025.
Here is a look at the consolidated yearly financials of GlaxoSmithKline Pharmaceuticals:
| Heading | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | Rs 2,925.60 Crore | Rs 3,278.03 Crore | Rs 3,251.72 Crore | Rs 3,453.71 Crore | Rs 3,749.21 Crore |
| Net Profit | Rs 287.27 Crore | Rs 380.77 Crore | Rs 607.64 Crore | Rs 589.96 Crore | Rs 927.58 Crore |
| EPS | 31.35 | 99.29 | 36.08 | 41.14 | 54.52 |
| BVPS | 87.26 | 157.19 | 102.79 | 104.93 | 115.19 |
| ROE | 24.22 | 63.64 | 35.41 | 33.42 | 47.67 |
| Debt to Equity | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
The revenue for the year ending March 2025 increased to Rs 3,749.21 Crore compared to Rs 3,453.71 Crore in March 2024. Net profit also rose to Rs 927.58 Crore in March 2025 from Rs 589.96 Crore in March 2024. The Earnings per share (EPS) increased to 54.52 in March 2025 from 41.14 in March 2024.
GlaxoSmithKline Pharmaceuticals - Key Ratios
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|
| P/E (x) | 45.96 | 16.79 | 36.72 | 47.32 | 52.83 |
| P/B (x) | 16.51 | 10.58 | 12.88 | 18.52 | 24.98 |
| EV/EBITDA (x) | 32.80 | 30.67 | 23.51 | 30.89 | 35.77 |
| P/S (x) | 8.34 | 8.59 | 6.90 | 9.53 | 13.00 |
| Debt to Equity (x) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
GlaxoSmithKline Pharmaceuticals Corporate Actions
GlaxoSmithKline Pharmaceuticals announced on August 25, 2025, its foray into Oncology with Jemperli and Zejula, bringing precision therapies for Gynaecological Cancers. The company had a final dividend of Rs 42 per share (420%) with effective date of May 30, 2025.
The company had previously announced a bonus issue on July 24, 2018, with existing ratio of 1:1, Ex Bonus Date: Sep 11, 2018.
With the stock's last traded price at Rs 2,748.00, GlaxoSmithKline Pharmaceuticals has seen a decline of 2.15% in today's session.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
